90%

of rheumatologists agree AVISE® significantly reduces the time to diagnosis1



Specialty Rheumatology Laboratory

Diagnosing and managing autoimmune rheumatic diseases is complex, you need to have confidence in the quality of your lab results. AVISE® testing is performed exclusively in Exagen’s centralized rheumatology laboratory giving you consistently accurate results. We also have a dedicated physician support team guided by licensed rheumatology advisors.

87% of rheumatologists agree AVISE® brings state of the art testing to rheumatology

Image

Graph showing Increasing likelihood of SLE

Unique Algorithm and Biomarkers

AVISE has a proprietary discovery and validation process for accurate and timely detection and disease management. Our two-tier algorithm applies CB-CAPs and other SLE-associated markers to our unique AVISE Lupus Index, turning isolated data points into actionable information for better clinical decisions.2


Image

Accuracy is Our Top Priority

We exceed expectations by combining extensive training and expertise with state-of-the-art technology. Exagen is proud to be the first U.S. clinical lab to complete an in-house validation of digital immunofluorescence.

85% of rheumatologists report AVISE® eliminates more false positives than general reference labs

Image


A Glimpse into Our Advanced Methods

ELISA-ANA

ANA is initially performed by a special ELISA assay that includes HEp-2 extract to improve sensitivity

HEp-2 ANA

All ANA tests are also processed using the gold standard HEp-2 immunofluorescent substrate

Testing Validation

HEp-2 Immunofluorescence Assay (IFA) results are analyzed with digital microscopy before undergoing human review and confirmation

Crithidia IFA

For dsDNA testing, Exagen uses a high-quality ELISA assay and all positive results are confirmed by Crithidia IFA




Real world evidence confirms that AVISE enables decisive clinical action in the differential diagnosis of SLE, superior to standard of care

Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements.

Putterman C, Furie R, Ramsey-Goldman R, et al. Lupus Sci Med. 2014;1(1):1-8.

View full study
Cell-bound complement activation products in systemic lupus erythematosus: Comparison with anti-double-stranded DNA and standard complement measurements.

Putterman C, Furie R, Ramsey-Goldman R, et al. Lupus Sci Med. 2014;1(1):1-8.

View full study
The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.

Mossell J, Goldman JA, Barken D, Alexander RV. Open Rheumatol J. 2016;10(1):71-80.

View full study
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.

Wallace DJ, Alexander RV, O’Malley T, et al. Lupus Sci Med. 2019;6(1):6-11.

View full study
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus.

Ramsey‐Goldman R, Alexander RV, Massarotti EM, et al.
Arthritis Rheumatol. 2020;72(1):78-88.

View full study
Connective Tissue Disease test in predicting lupus diagnosis and progression.

Liang E, Taylor M, McMahon M. Utility of the AVISE Lupus Sci Med. 2020;7(1):4-6.

View full study
Load More
Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).

Clarke AE, Weinstein A, Piscitello A, et al. ACR Open Rheumatology. 2020;0(0):1-11.

View full study
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.

Alexander RV, Rey DS, Conklin J, et al.
Lupus Sci Med. 2021;8(1):e000528.

View full study
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

O'Malley T, et al. Journal of Managed Care + Specialty Pharmacy 2022.

View full study
Image

Accelerated Time to Diagnosis Leads to Better Patient Care

Diagnosing and managing autoimmune rheumatic diseases is complex, you need to have confidence in the quality of your lab results. AVISE® testing is performed exclusively in Exagen’s centralized rheumatology laboratory giving you consistently accurate results. We also have a dedicated physician support team guided by licensed rheumatology advisors.



  • 58 Serial Tests

    The average number of general tests a patient endures.3

  • 6 Years to Diagnosis

    Inadequate diagnostic tools create delays in diagnosis.4

  • Delayed Treatment

    Imprecise testing data leads to delayed treatment and results in major organ involvement for most SLE patients.

  • Increased Disease Burden

    The data shows that diagnostic delay from the time of symptom onset is significantly associated with increased disease activity, SLE-damage, fatigue, and decreased quality of life.5


Image

Would you like more information? Speak to an AVISE representative.

Contact Representative